| Title | Symptom control after different duration of triptorelin treatment following conservative surgery for deep infiltrating endometriosis Post-hoc analysis of a multicentre, prospective, real-world study |
| Authors | Sun, Wenting Hua, Keqin Hong, Li Zhang, Juxin Hao, Min Wang, Jianliu Zhang, Jun Perrot, Valerie Li, Hongbo Zhang, Xinmei |
| Affiliation | Zhejiang Univ, Sch Med, Womens Hosp, Gynaecol Dept, Hangzhou, Peoples R China Fudan Univ, Obstet & Gynecol Hosp, Gynaecol Dept, Shanghai, Peoples R China Wuhan Univ, Med Fac, Remin Hosp, Gynaecol Dept, Wuhan, Hubei, Peoples R China Henan Prov Peoples Hosp, Gynaecol Dept, Zhengzhou, Henan, Peoples R China Shanxi Univ, Hosp 2, Gynaecol Dept, Taiyuan, Shanxi, Peoples R China Peking Univ, Peoples Hosp, Gynaecol Dept, Beijing, Peoples R China Capital Med Univ, Beijing Anzhen Hosp, Gynaecol Dept, Beijing, Peoples R China Ipsen, Clin Stat Dept, Boulogne Billancourt, France Ipsen Beijing Pharmaceut Sci & Technol Dev Co Ltd, Med Affairs Dept, Beijing, Peoples R China |
| Keywords | LAPAROSCOPIC SURGERY MANAGEMENT |
| Issue Date | 30-Jul-2021 |
| Publisher | MEDICINE |
| Abstract | Triptorelin has been used after surgery in deep infiltrating endometriosis. This post-hoc analysis aimed to evaluate symptom control between patients receiving 1-3 triptorelin injections and those receiving 4-6 injections within 24 months of conservative surgery for deep infiltrating endometriosis, in the real-world. Included patients were divided into two groups (received up to 3 months injections in group A, 4-6 injections in group B) based on the numbers of triptorelin (Diphereline, 3.75 mg intramuscular injection once every 28 days for up to 24 weeks) administration. Evolution in score of pain intensity at 3, 6, 9, 12, 18, and 24 months after primary triptorelin administration and symptom improvement/recurrence rates between two groups were compared. Symptoms of pain intensity were assessed using a visual analogue scale (VAS) with a range from 0 to 10 cm. An improvement in symptoms was defined as a reduction of at least 3 cm or 3 units from pre-surgery levels. 156 patients in group A and 228 in group B. Pain symptom score (mean +/- standard deviation) diminished to a nadir at 3-months for group A and 6-months for group B; at 6-months nadir scores were significantly lower in group B (0.9 +/- 1.7 vs 0.4 +/- 1.2 respectively, P = .002). No significant difference for pain symptom scores between both groups at 24-months (P = .269). The 6-month and 24-month cumulative improvement rates of pain (80.6% vs 89.8%, P = .014 and 82.6% vs 90.7%, P = .025) and gastro-intestinal symptoms (61.0% vs 80.8%, P = .022 and 61.0% vs 83.3%, P = .008) were significantly higher in group B, whereas there was no significant difference in rates of menstrual disorders and urinary symptoms. There is no significant difference for 12-months and 24-months cumulative recurrence rates of total symptoms between both groups (11.3% vs 13.8%, P = .568 and 16.1% vs 26.0%, P = .094). In women with deep infiltrating endometriosis, longer treatment with triptorelin following conservative surgery was associated with a decrease in symptom intensity and greater improvement of pain symptoms in the short-term and greater improvement of gastro-intestinal symptoms in the long-term. Trial registration number: ClinicalTrials.gov, NCT01942369. |
| URI | http://hdl.handle.net/20.500.11897/622999 |
| ISSN | 0025-7974 |
| DOI | 10.1097/MD.0000000000026753 |
| Indexed | SCI(E) |
| Appears in Collections: | 人民医院 |
